Efficacy and safety of sofosbuvir/velpatasvir plus ribavirin for 12 or 24 weeks in genotype 1 or 2 HCV-infected japanese patients with prior treatment failure to DAA-based regimens

Authors
Category Primary study
JournalHepatology
Year 2017
This article has no abstract
Epistemonikos ID: 9fce6e4a7dcfae9845f0cda627f8f14bdddc7f12
First added on: Feb 08, 2025